• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Creatine kinase levels in asthma patients receiving interleukin-5 therapy.

作者信息

Kavanagh Grace A, Casey Deborah, Cusack Ruth P, Plant Barry J, Murphy Desmond M

机构信息

The Department of Respiratory Medicine, Cork University Hospital, Cork, Ireland.

The Department of Respiratory Medicine, Galway University Hospital, Galway, Ireland.

出版信息

Ther Adv Respir Dis. 2022 Jan-Dec;16:17534666221122475. doi: 10.1177/17534666221122475.

DOI:10.1177/17534666221122475
PMID:37013792
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9478696/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a405/9478696/e49c2b2f9c10/10.1177_17534666221122475-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a405/9478696/486f9cc60d59/10.1177_17534666221122475-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a405/9478696/44d95df0a978/10.1177_17534666221122475-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a405/9478696/e49c2b2f9c10/10.1177_17534666221122475-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a405/9478696/486f9cc60d59/10.1177_17534666221122475-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a405/9478696/44d95df0a978/10.1177_17534666221122475-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a405/9478696/e49c2b2f9c10/10.1177_17534666221122475-fig3.jpg

相似文献

1
Creatine kinase levels in asthma patients receiving interleukin-5 therapy.接受白细胞介素-5治疗的哮喘患者的肌酸激酶水平。
Ther Adv Respir Dis. 2022 Jan-Dec;16:17534666221122475. doi: 10.1177/17534666221122475.
2
Creatine kinase activity in patients with brittle asthma treated with long term subcutaneous terbutaline.长期皮下注射特布他林治疗的脆性哮喘患者的肌酸激酶活性
Thorax. 1991 Aug;46(8):580-3. doi: 10.1136/thx.46.8.580.
3
[PERSONALIZED TREATMENT OF ASTHMA: THE ISSUE OF ANTI-INTERLEUKIN-5 ANTIBODIES].[哮喘的个性化治疗：抗白细胞介素-5抗体问题]
Rev Med Liege. 2015 May-Jun;70(5-6):306-9.
4
Interleukin-5 Antagonists Usher in a New Generation of Asthma Therapy.白细胞介素-5拮抗剂引领新一代哮喘治疗。
Curr Allergy Asthma Rep. 2016 Nov;16(11):80. doi: 10.1007/s11882-016-0662-1.
5
Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.奥马珠单抗可作为严重哮喘中慢性口服皮质类固醇替代疗法。
Respir Med. 2019 Apr;150:51-62. doi: 10.1016/j.rmed.2019.02.003. Epub 2019 Feb 7.
6
Controversies in Allergy: Should Severe Asthma with Eosinophilic Phenotype Always Be Treated with Anti-IL-5 Therapies.过敏领域的争议：嗜酸性粒细胞型重度哮喘是否都应采用抗IL-5疗法进行治疗。
J Allergy Clin Immunol Pract. 2019 May-Jun;7(5):1430-1436. doi: 10.1016/j.jaip.2019.03.010. Epub 2019 Apr 5.
7
Rationale and clinical results of inhibiting interleukin-5 for the treatment of severe asthma.抑制白细胞介素-5 治疗严重哮喘的原理和临床结果。
Curr Allergy Asthma Rep. 2013 Oct;13(5):469-76. doi: 10.1007/s11882-013-0379-3.
8
Targeting Interleukin-5 or Interleukin-5Rα: Safety Considerations.靶向白细胞介素-5或白细胞介素-5Rα：安全性考量
Drug Saf. 2017 Jul;40(7):559-570. doi: 10.1007/s40264-017-0522-5.
9
Interleukin-5 Inhibitors for Severe Asthma: Rationale and Future Outlook.用于重度哮喘的白细胞介素-5抑制剂：理论依据与未来展望。
BioDrugs. 2017 Apr;31(2):93-103. doi: 10.1007/s40259-017-0215-8.
10
New anti-asthma therapies: suppression of the effect of interleukin (IL)-4 and IL-5.新型抗哮喘疗法：抑制白细胞介素（IL）-4和IL-5的作用。
Eur Respir J. 2001 Mar;17(3):499-506. doi: 10.1183/09031936.01.17304990.

本文引用的文献

1
Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma.特泽布尔单抗在成人和青少年重症、未控制哮喘中的应用。
N Engl J Med. 2021 May 13;384(19):1800-1809. doi: 10.1056/NEJMoa2034975.
2
Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial.贝那鲁肽治疗重度嗜酸性粒细胞性哮喘患者的疗效发作和对健康相关生活质量的影响、恶化率、肺功能和鼻息肉症状：一项随机、对照、3b 期试验。
Lancet Respir Med. 2021 Mar;9(3):260-274. doi: 10.1016/S2213-2600(20)30414-8. Epub 2020 Dec 22.
3
Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme.
美泊利珠单抗治疗重度嗜酸性粒细胞性哮喘和糖皮质激素依赖患者的疗效：来自法国早期准入项目的结果。
Eur Respir J. 2020 Jun 25;55(6). doi: 10.1183/13993003.02345-2019. Print 2020 Jun.
4
The effectiveness of Reslizumab in severe asthma treatment: a real-world experience.雷西珠单抗治疗重度哮喘的疗效：真实世界经验。
Respir Res. 2019 Dec 20;20(1):289. doi: 10.1186/s12931-019-1251-3.
5
Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2).度普利尤单抗单药治疗中重度特应性皮炎成人患者的疗效和安全性：两项 3 期随机临床试验（LIBERTY AD SOLO 1 和 LIBERTY AD SOLO 2）的汇总分析。
J Dermatol Sci. 2019 May;94(2):266-275. doi: 10.1016/j.jdermsci.2019.02.002. Epub 2019 Mar 12.
6
Role of Biologics in Asthma.生物制剂在哮喘中的作用。
Am J Respir Crit Care Med. 2019 Feb 15;199(4):433-445. doi: 10.1164/rccm.201810-1944CI.
7
Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma.评估美泊利珠单抗治疗重度嗜酸性粒细胞性哮喘的长期安全性和临床应答的持久性。
J Allergy Clin Immunol. 2019 May;143(5):1742-1751.e7. doi: 10.1016/j.jaci.2018.09.033. Epub 2018 Oct 23.
8
Asymptomatic hyperCKemia During Infliximab Therapy in Patients With Inflammatory Bowel Disease.炎症性肠病患者接受英夫利昔单抗治疗期间无症状性高肌酸激酶血症。
Inflamm Bowel Dis. 2018 May 18;24(6):1266-1271. doi: 10.1093/ibd/izy088.
9
Approach to asymptomatic creatine kinase elevation.无症状性肌酸激酶升高的处理方法。
Cleve Clin J Med. 2016 Jan;83(1):37-42. doi: 10.3949/ccjm.83a.14120.
10
A qualitative study of the impact of severe asthma and its treatment showing that treatment burden is neglected in existing asthma assessment scales.一项关于重度哮喘及其治疗影响的定性研究表明，现有哮喘评估量表忽视了治疗负担。
Qual Life Res. 2015 Mar;24(3):631-9. doi: 10.1007/s11136-014-0801-x. Epub 2014 Sep 9.